ES2643369T3 - Formulación farmacéutica oral de liberación modificada que contiene gliclazida - Google Patents

Formulación farmacéutica oral de liberación modificada que contiene gliclazida Download PDF

Info

Publication number
ES2643369T3
ES2643369T3 ES14757858.7T ES14757858T ES2643369T3 ES 2643369 T3 ES2643369 T3 ES 2643369T3 ES 14757858 T ES14757858 T ES 14757858T ES 2643369 T3 ES2643369 T3 ES 2643369T3
Authority
ES
Spain
Prior art keywords
modified
pharmaceutical formulation
formulation containing
oral pharmaceutical
release oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14757858.7T
Other languages
English (en)
Inventor
Roberto Valducci
Serozh Avanessian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma International SpA
Original Assignee
Valpharma International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma International SpA filed Critical Valpharma International SpA
Application granted granted Critical
Publication of ES2643369T3 publication Critical patent/ES2643369T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES14757858.7T 2013-08-01 2014-08-01 Formulación farmacéutica oral de liberación modificada que contiene gliclazida Active ES2643369T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI20130184 2013-08-01
IT000184A ITFI20130184A1 (it) 2013-08-01 2013-08-01 Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
PCT/EP2014/066599 WO2015014987A1 (en) 2013-08-01 2014-08-01 A modified-release oral pharmaceutical formulation containing gliclazide

Publications (1)

Publication Number Publication Date
ES2643369T3 true ES2643369T3 (es) 2017-11-22

Family

ID=49226301

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14757858.7T Active ES2643369T3 (es) 2013-08-01 2014-08-01 Formulación farmacéutica oral de liberación modificada que contiene gliclazida

Country Status (7)

Country Link
US (1) US20160158196A1 (es)
EP (1) EP3027177B1 (es)
JP (1) JP2016527261A (es)
ES (1) ES2643369T3 (es)
IT (1) ITFI20130184A1 (es)
RU (1) RU2016105601A (es)
WO (1) WO2015014987A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
KR20040044992A (ko) * 2001-09-28 2004-05-31 썬 파마슈티컬 인더스트리스 리미티드 당뇨병 치료용 투여형태
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006123213A1 (en) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Modified release formulations of gliclazide
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif

Also Published As

Publication number Publication date
US20160158196A1 (en) 2016-06-09
ITFI20130184A1 (it) 2015-02-02
RU2016105601A (ru) 2017-08-23
EP3027177A1 (en) 2016-06-08
JP2016527261A (ja) 2016-09-08
WO2015014987A1 (en) 2015-02-05
EP3027177B1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
ES2642354T3 (es) Bastidor de retención para módulos de conectores de enchufe
ES2644844T3 (es) Mecanismo de soporte
ES2471951T3 (es) Procedimiento y dispositivo para el estampado en caliente
FR21C1059I2 (fr) Compositions pharmaceutiques
ES2642212T3 (es) Cierre de cremallera
ES2644468T3 (es) Transgén sintético de la metilmalonil-CoA mutasa para el tratamiento de la acidemia metilmalónica (MMA) de clase MUT
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2014002316A1 (es) Formulacion farmacéutica que comprende un anticuerpo anti tnf alfa
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
FR3002736B1 (fr) Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3004882B1 (fr) Dispositif d'acquisition d'images bimode
ES2643848T3 (es) Método para cuantificar dosis UV desinfectantes usando indicadores
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
ES2643814T3 (es) Carretilla elevadora equipada con medios de estabilización
FR3000606B1 (fr) Capteur d'image
MA44720A (fr) Comprimés à désintégration orale
ES2644847T3 (es) Máquina agrícola
ES2641554T3 (es) Kit de piezas para colocación de anclaje quirúrgico
ES2642175T3 (es) Cable
ES2644995T3 (es) Módulo de filtro
ES2644293T3 (es) Dispositivo de compresión médico
ES2643369T3 (es) Formulación farmacéutica oral de liberación modificada que contiene gliclazida
ES2644989T3 (es) Mecanismo de activación para encendedor
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
ES2642624T3 (es) Polipéptidos de leptina canina modificados